131 related articles for article (PubMed ID: 15652904)
21. Chronic COX inhibition reduces diabetes-induced hyperfiltration, proteinuria, and renal pathological markers in 36-week B6-Ins2(Akita) mice.
Nasrallah R; Robertson SJ; Hébert RL
Am J Nephrol; 2009; 30(4):346-53. PubMed ID: 19609076
[TBL] [Abstract][Full Text] [Related]
22. Anastrozole and celecoxib for endometriosis treatment, good to keep them apart?
Olivares CN; Bilotas MA; Ricci AG; Barañao RI; Meresman GF
Reproduction; 2013 Feb; 145(2):119-26. PubMed ID: 23148086
[TBL] [Abstract][Full Text] [Related]
23. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials.
White WB; West CR; Borer JS; Gorelick PB; Lavange L; Pan SX; Weiner E; Verburg KM
Am J Cardiol; 2007 Jan; 99(1):91-8. PubMed ID: 17196469
[TBL] [Abstract][Full Text] [Related]
24. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK
Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912
[TBL] [Abstract][Full Text] [Related]
25. Blood pressure in Native Americans switched from celecoxib to rofecoxib.
Fredy J; Diggins DA; Morrill GB
Ann Pharmacother; 2005 May; 39(5):797-802. PubMed ID: 15797981
[TBL] [Abstract][Full Text] [Related]
26. Genistein causes regression of endometriotic implants in the rat model.
Yavuz E; Oktem M; Esinler I; Toru SA; Zeyneloglu HB
Fertil Steril; 2007 Oct; 88(4 Suppl):1129-34. PubMed ID: 17559846
[TBL] [Abstract][Full Text] [Related]
27. Celecoxib: new indication. Colorectal cancer: no preventive benefit.
Prescrire Int; 2006 Feb; 15(81):13-5. PubMed ID: 16548099
[TBL] [Abstract][Full Text] [Related]
28. A selective cyclooxygenase-2 inhibitor suppresses the growth of endometriosis xenografts via antiangiogenic activity in severe combined immunodeficiency mice.
Ozawa Y; Murakami T; Tamura M; Terada Y; Yaegashi N; Okamura K
Fertil Steril; 2006 Oct; 86(4 Suppl):1146-51. PubMed ID: 16962108
[TBL] [Abstract][Full Text] [Related]
29. Celecoxib in the treatment of primary dysmenorrhea: results from two randomized, double-blind, active- and placebo-controlled, crossover studies.
Daniels S; Robbins J; West CR; Nemeth MA
Clin Ther; 2009 Jun; 31(6):1192-208. PubMed ID: 19695387
[TBL] [Abstract][Full Text] [Related]
30. Need for common internal controls when assessing the relative efficacy of pharmacologic agents using a meta-analytic approach: case study of cyclooxygenase 2-selective inhibitors for the treatment of osteoarthritis.
Lee C; Hunsche E; Balshaw R; Kong SX; Schnitzer TJ
Arthritis Rheum; 2005 Aug; 53(4):510-8. PubMed ID: 16082648
[TBL] [Abstract][Full Text] [Related]
31. The hepatic safety and tolerability of the cyclooxygenase-2 selective NSAID celecoxib: pooled analysis of 41 randomized controlled trials.
Soni P; Shell B; Cawkwell G; Li C; Ma H
Curr Med Res Opin; 2009 Aug; 25(8):1841-51. PubMed ID: 19530981
[TBL] [Abstract][Full Text] [Related]
32. Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study.
Rahme E; Bardou M; Dasgupta K; Toubouti Y; Ghosn J; Barkun AN
Rheumatology (Oxford); 2007 Feb; 46(2):265-72. PubMed ID: 16844699
[TBL] [Abstract][Full Text] [Related]
33. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk.
Solomon DH; Avorn J; Stürmer T; Glynn RJ; Mogun H; Schneeweiss S
Arthritis Rheum; 2006 May; 54(5):1378-89. PubMed ID: 16645966
[TBL] [Abstract][Full Text] [Related]
34. Targeting cyclooxygenase-2 reduces overt toxicity toward low-dose vinblastine and extends survival of juvenile mice with Friend disease.
Cervi D; Klement G; Stempak D; Baruchel S; Koki A; Ben-David Y
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):712-9. PubMed ID: 15701860
[TBL] [Abstract][Full Text] [Related]
35. Effects of a selective cyclooxygenase-2 inhibitor on endometrial epithelial cells from patients with endometriosis.
Olivares C; Bilotas M; Buquet R; Borghi M; Sueldo C; Tesone M; Meresman G
Hum Reprod; 2008 Dec; 23(12):2701-8. PubMed ID: 18716040
[TBL] [Abstract][Full Text] [Related]
36. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
Spalding WM; Reeves MJ; Whelton A
Am J Ther; 2007; 14(1):3-12. PubMed ID: 17303969
[TBL] [Abstract][Full Text] [Related]
37. Valdecoxib is associated with improved dyspepsia-related health compared with nonspecific NSAIDs in patients with osteoarthritis or rheumatoid arthritis.
Rabeneck L; Goldstein JL; Vu A; Mayne TJ; Rublee DA
Am J Gastroenterol; 2005 May; 100(5):1043-50. PubMed ID: 15842577
[TBL] [Abstract][Full Text] [Related]
38. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
Rahme E; Nedjar H
Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138
[TBL] [Abstract][Full Text] [Related]
39. The effects of some nonsteroidal anti-inflammatory drugs on experimental induced gastric ulcers in rats.
Batu OS; Erol K
Inflammopharmacology; 2007 Dec; 15(6):260-5. PubMed ID: 18236017
[TBL] [Abstract][Full Text] [Related]
40. The anti-proliferative potency of celecoxib is not a class effect of coxibs.
Schiffmann S; Maier TJ; Wobst I; Janssen A; Corban-Wilhelm H; Angioni C; Geisslinger G; Grösch S
Biochem Pharmacol; 2008 Jul; 76(2):179-87. PubMed ID: 18547544
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
